Table 1 Correlation between the clinicopathological characteristics and IGF2BP3 expression
From: The role of IGF2BP3/SPOP/c-Myc loop in paclitaxel resistance of endometrial cancer
Characteristic | Number | IGF2BP3, n (%) | ||||
|---|---|---|---|---|---|---|
Negative | Low positive | High positive | χ2 | P value | ||
Age (years), n (%) | 0.748 | 0.688 | ||||
≤60 | 38 | 15 (39.47%) | 18 (47.37%) | 5 (13.16%) | ||
> 60 | 22 | 11 (50.00%) | 8 (36.36%) | 3 (13.64%) | ||
Height (cm), n (%) | 0.432 | 0.806 | ||||
≤160 | 42 | 17 (40.48%) | 19 (45.24%) | 6 (14.28%) | ||
> 160 | 16 | 8 (50.00%) | 6 (37.50%) | 2 (12.50%) | ||
Weight (kg), n (%) | 1.322 | 0.516 | ||||
≤60 | 33 | 13 (39.39%) | 14 (42.43%) | 6 (18.18%) | ||
> 60 | 25 | 12 (48.00%) | 11 (44.00%) | 2 (8.00%) | ||
BMI (kg/m2), n (%) | 0.512 | 0.774 | ||||
≤24 | 30 | 12 (40.00%) | 13 (43.33%) | 5 (16.67%) | ||
> 24 | 28 | 13 (46.43%) | 12 (42.86%) | 3 (10.71%) | ||
Tumor number | 1.248 | 0.536 | ||||
Single | 33 | 15 (45.46%) | 13 (39.39%) | 5 (15.15%) | ||
Multiple | 20 | 7 (35.00%) | 11 (55.00%) | 2 (10.00%) | ||
Tumor size (cm), n (%) | 1.069 | 0.586 | ||||
≤4 | 40 | 16 (40.00%) | 19 (47.50%) | 5 (12.50%) | ||
> 4 | 10 | 5 (50.00%) | 3 (30.00%) | 2 (20.00%) | ||
Histological grade, n (%) | 3.835 | 0.429 | ||||
G1 | 23 | 9 (39.13%) | 10 (43.48%) | 4 (17.39%) | ||
G2 | 24 | 15 (62.50%) | 8 (33.33%) | 1 (4.17%) | ||
G3 | 5 | 2 (40.00%) | 2 (40.00%) | 1 (20.00%) | ||
T, n (%) | 1.298 | 0.862 | ||||
T1 | 50 | 21 (42.00%) | 21 (42.00%) | 8 (16.00%) | ||
T2 | 3 | 2 (66.67%) | 1 (33.33%) | 0 (0.00%) | ||
T3 | 2 | 1 (50.00%) | 1 (50.00%) | 0 (0.00%) | ||
N, n (%) | 2.962 | 0.227 | ||||
N0 | 22 | 14 (63.63%) | 5 (22.73%) | 3 (13.64%) | ||
N1 | 0 | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | ||
N2 | 1 | 0 (0.00%) | 1 (100.00%) | 0 (0.00%) | ||
M, n (%) | 2.962 | 0.227 | ||||
M0 | 22 | 14 (63.63%) | 5 (22.73%) | 3 (13.64%) | ||
M1 | 1 | 0 (0.00%) | 1 (100.00%) | 0 (0.00%) | ||
FIGO stage, n (%) | 4.229 | 0.646 | ||||
I | 18 | 11 (61.11%) | 4 (22.22%) | 3 (16.67%) | ||
II | 3 | 2 (66.67%) | 1 (33.33%) | 0 (0.00%) | ||
III | 1 | 1 (100.00%) | 0 (0.00%) | 0 (0.00%) | ||
IV | 1 | 0 (0.00%) | 1 (100.00%) | 0 (0.00%) | ||
Menopause, n (%) | 0.793 | 0.673 | ||||
YES | 19 | 11 (57.89%) | 5 (26.32%) | 3 (15.79%) | ||
NO | 4 | 3 (75.00%) | 1 (25.00%) | 0 (0.00%) | ||
HPV, n (%) | - | - | ||||
YES | 0 | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | ||
NO | 56 | 24 (42.86%) | 26 (46.43%) | 6 (10.71%) | ||
Chemotherapy, n (%) | 1.330 | 0.514 | ||||
YES | 1 | 0 (0.00%) | 1 (100.00%) | 0 (0.00%) | ||
NO | 66 | 30 (45.46%) | 28 (42.42%) | 8 (12.12%) | ||
Radiotherapy, n (%) | 1.252 | 0.535 | ||||
YES | 1 | 1 (100.00%) | 0 (0.00%) | 0 (0.00%) | ||
NO | 66 | 29 (43.94%) | 29 (43.94%) | 8 (12.12%) | ||
Hypertension, n (%) | 2.750 | 0.253 | ||||
YES | 17 | 5 (29.41%) | 10 (58.82%) | 2 (11.77%) | ||
NO | 49 | 25 (51.02%) | 18 (36.73%) | 6 (12.25%) | ||
Diabetes, n (%) | 0.871 | 0.647 | ||||
YES | 7 | 2 (28.57%) | 4 (57.14%) | 1 (14.29%) | ||
NO | 53 | 25 (47.17%) | 22 (41.51%) | 6 (11.32%) | ||
Surgery, n (%) | 3.518 | 0.172 | ||||
YES | 22 | 13 (59.09%) | 6 (27.27%) | 3 (13.64%) | ||
NO | 45 | 17 (37.78%) | 23 (51.11%) | 5 (11.11%) | ||
Smoking, n (%) | - | - | ||||
YES | 0 | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | ||
NO | 60 | 27 (45.00%) | 26 (43.33%) | 7 (11.67%) | ||
Drinking, n (%) | - | - | ||||
YES | 0 | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | ||
NO | 67 | 30 (44.78%) | 29 (43.28%) | 8 (11.94%) | ||
ER, n (%) | 10.120 | 0.038 | ||||
Negative | 1 | 0 (0.00%) | 0 (0.00%) | 1 (100.00%) | ||
Low positive | 42 | 20 (47.62%) | 17 (40.48%) | 5 (11.90%) | ||
High positive | 4 | 0 (0.00%) | 2 (50.00%) | 2 (50.00%) | ||
PR, n (%) | 16.250 | 0.013 | ||||
- | 2 | 0 (0.00%) | 0 (0.00%) | 2 (100.00%) | ||
+ | 47 | 22 (46.81%) | 20 (42.55%) | 5 (10.64%) | ||
++ | 5 | 2 (40.00%) | 3 (60.00%) | 0 (0.00%) | ||
+++ | 1 | 0 (0.00%) | 1 (100.00%) | 0 (0.00%) | ||
Vimentin, n (%) | 2.129 | 0.907 | ||||
- | 3 | 2 (66.67%) | 1 (33.33%) | 0 (0.00%) | ||
+ | 47 | 20 (42.55%) | 20 (42.55%) | 7 (14.90%) | ||
++ | 3 | 1 (33.33%) | 2 (66.67%) | 0 (0.00%) | ||
+++ | 2 | 1 (50.00%) | 1 (50.00%) | 0 (0.00%) | ||
p53, n (%) | 7.413 | 0.116 | ||||
- | 5 | 3 (60.00%) | 2 (40.00%) | 0 (0.00%) | ||
+ | 47 | 22 (46.81%) | 20 (42.55%) | 5 (10.64%) | ||
++ | 0 | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | ||
+++ | 4 | 0 (0.00%) | 2 (50.00%) | 2 (50.00%) | ||
